4D Pharma has announced the completion of an accelerated book build (ABB) raising £22m (gross) by means of a Placing and Subscription of 44m new ordinary shares with existing and new investors at 50p/share. Proceeds will fund the ongoing development of clinical candidates and two key data readouts from the MRx0518 and Blautix programmes is expected over the coming months. **As Nomad, and joint broker and bookrunner to the placing for 4D Pharma, we are restricted and can therefore provid
19 Feb 2020
£22m equity raise to reach key data readouts
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
£22m equity raise to reach key data readouts
- Published:
19 Feb 2020 -
Author:
Edward Thomason -
Pages:
3
4D Pharma has announced the completion of an accelerated book build (ABB) raising £22m (gross) by means of a Placing and Subscription of 44m new ordinary shares with existing and new investors at 50p/share. Proceeds will fund the ongoing development of clinical candidates and two key data readouts from the MRx0518 and Blautix programmes is expected over the coming months. **As Nomad, and joint broker and bookrunner to the placing for 4D Pharma, we are restricted and can therefore provid